Hormonal markers for prostate cancer and treatment of patients

Main Article Content

O.V. Syniachenko
M.I. Paliy
Yu.V. Dumansky
M.V. Yermolaieva
O.Yu. Stoliarova

Abstract

Background. In the structure of oncological pathology in men, prostate cancer occupies a leading position, while being the second most frequent cause of death in cases of malignant neoplasms. The incidence and mortality of prostate cancer, which is a hormone-dependent tumor, increase every year around the world. Among the biomarkers of the tumor process in prostate cancer, such sex and gonadotropic hormones as testosterone (TS) and luteinizing hormone (lutropin, LT) are discussed. Partially, this concerns a functional analogue of insulin — insulin-like growth factor 1 (IGF). The purpose of the study was to assess the clinical and prognostic significance of hormonal tumor markers (TS, LT, IGF) in the blood of patients with prostate cancer. Materials and methods. The study included 195 men with prostate cancer aged 52 to 82 years. The exclusion criteria were patients with less than stage II of the pathological process. The duration since the diagnosis of the disease ranged from 5 months to 17 years. Adenocarcinoma was diagnosed in 94 % of the examined patients, metastases in the lymph nodes were found in 39 %, in distant organs — in 19 %, in the skeleton — in 28 % of cases. Serum levels of TS and LT were studied by immunochemical analysis, and the content of IGF — by enzyme immunoassay. Results. An increase in the level of hormonal markers of prostate cancer, such as TS and IGF, is observed in the blood of 46 and 100 % of individuals, respectively, depending on the nature of the tumor process and its metastasis. The five-year survival rate of patients with prostate cancer depends on the initial Gleason criterion, the method of radiation therapy and the concurrent administration of anti-androgen hormone therapy. In the course of the treatment measures, the content of hormonal markers of the tumor process (TS, LT, IGF) in the blood significantly decreases, which is determined by the initial nature of the course of the disease. Conclusions. Studied hormonal biomarkers of prostate cancer are involved in the pathogenetic constructions of the disease and have diagnostic and prognostic significance in the course of treatment.

Article Details

How to Cite
Syniachenko, O., M. Paliy, Y. Dumansky, M. Yermolaieva, and O. Stoliarova. “Hormonal Markers for Prostate Cancer and Treatment of Patients”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 16, no. 6, Oct. 2020, pp. 483-8, doi:10.22141/2224-0721.16.6.2020.215387.
Section
Original Researches

References

Gesmundo I, Di Blasio L, Banfi D, et al. Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase. Cancer Lett. 2019 May 1;449:252-262. doi:10.1016/j.canlet.2019.02.028.

Ouellette V, Côté MF, Gaudreault RC, Tajmir-Riahi HA, Bérubé G. Second-generation testosterone-platinum(II) hybrids for site-specific treatment of androgen receptor positive prostate cancer: Design, synthesis and antiproliferative activity. Eur J Med Chem. 2019 Oct 1;179:660-666. doi:10.1016/j.ejmech.2019.06.090.

Cheaito KA, Bahmad HF, Hadadeh O, et al. EMT Markers in Locally-Advanced Prostate Cancer: Predicting Recurrence? Front Oncol. 2019 Mar 11;9:131. doi:10.3389/fonc.2019.00131.

Lang R, Rolny V, Leinenbach A, et al. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness. Tumour Biol. 2019 Mar;41(3):1010428319827223. doi:10.1177/1010428319827223.

Xu W, Qian J, Zeng F, et al. Protein kinase Ds promote tumor angiogenesis through mast cell recruitment and expression of angiogenic factors in prostate cancer microenvironment. J Exp Clin Cancer Res. 2019 Mar 6;38(1):114. doi:10.1186/s13046-019-1118-y.

Zhao JG, Nie L, Chen XQ, Chen N, Zeng H. The subgroup analysis of the prognostic value of the intraductal carcinoma of the prostate in patients with metastatic prostate cancer. Zhonghua Wai Ke Za Zhi. 2019 Jun 1;57(6):422-427. doi:10.3760/cma.j.issn.0529-5815.2019.06.006. (in Chinese).

Cheung AS, Gray HA, Schache AG, et al. Biomechanical Leg Muscle Function During Stair Ambulation in Men Receiving Androgen Deprivation Therapy. J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1715-1722. doi:10.1093/gerona/glz169.

Morote J, Comas I. Replay by authors: Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer. Urol Oncol. 2019 Sep;37(9):571. doi:10.1016/j.urolonc.2019.05.016.

Wang W, Chen ZX, Guo DY, Tao YX. Regulation of prostate cancer by hormone-responsive G protein-coupled receptors. Pharmacol Ther. 2018 Nov;191:135-147. doi:10.1016/j.pharmthera.2018.06.005.

Pak S, Park SY, Shin TJ, et al. Association of Muscle Mass with Survival after Radical Prostatectomy in Patients with Prostate Cancer. J Urol. 2019 Sep;202(3):525-532. doi:10.1097/JU.0000000000000249.

Bedolla RG, Shah DP, Huang SB, Reddick RL, Ghosh R, Kumar AP. Receptor tyrosine kinase recepteur d'origine nantais as predictive marker for aggressive prostate cancer in African Americans. Mol Carcinog. 2019 Jun;58(6):854-861. doi:10.1002/mc.23002.

Morote J, Comas I, Planas J, et al. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy. Clin Genitourin Cancer. 2018 Apr;16(2):e491-e496. doi:10.1016/j.clgc.2017.10.025.

Shim M, Bang WJ, Oh CY, Lee YS, Cho JS. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide. Investig Clin Urol. 2019 Jul;60(4):244-250. doi:10.4111/icu.2019.60.4.244.

Cordero JA, Sancho G, Bonfill X. Population-based estimate of the use of intermittent androgen deprivation therapy in prostate cancer patients in Catalonia, Spain. Pharmacoepidemiol Drug Saf. 2019 Jun;28(6):796-803. doi:10.1002/pds.4744.

Shevach J, Chaudhuri P, Morgans AK. Adjuvant therapy in high-risk prostate cancer. Clin Adv Hematol Oncol. 2019 Jan;17(1):45-53.

Shimodaira K, Nakashima J, Nakagami Y, et al. Prognostic Value of Platelet Counts in Patients with Metastatic Prostate Cancer Treated with Endocrine Therapy. Urol J. 2020 Jan 26;17(1):42-49. doi:10.22037/uj.v0i0.4735.

Farhood B, Mortezaee K, Haghi-Aminjan H, et al. A systematic review of radiation-induced testicular toxicities following radiotherapy for prostate cancer. J Cell Physiol. 2019 Feb 10. doi:10.1002/jcp.28283.

Porcaro AB, Tafuri A, Sebben M, et al. Positive Association between Basal Total Testosterone Circulating Levels and Tumor Grade Groups at the Time of Diagnosis of Prostate Cancer. Urol Int. 2019;103(4):400-407. doi:10.1159/000500960.

Kardoust Parizi M, Abufaraj M, Fajkovic H, et al. Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis. Urol Oncol. 2019 Oct;37(10):637-646. doi:10.1016/j.urolonc.2019.06.007.

Vallat A, Pillot P, Lebâcle C, Irani J. Prognostic value of testosterone during androgene deprivation therapy. Prog Urol. 2019 Sep;29(10):510-523. doi:10.1016/j.purol.2019.06.002. (in French).

Yan Y, Chen Z, Xiao Y, Wang X, Qian K. Long non-coding RNA SNHG6 is upregulated in prostate cancer and predicts poor prognosis. Mol Biol Rep. 2019 Jun;46(3):2771-2778. doi:10.1007/s11033-019-04723-9.

Most read articles by the same author(s)